Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 456

1.

Comparison between the clinical characteristics of patients with adrenal incidentalomas and those with hypertension-associated adrenal tumors in a single center in Japan.

Aoe M, Okada A, Usui T, Manaka K, Nangaku M, Makita N.

Endocr J. 2020 Mar 25. doi: 10.1507/endocrj.EJ19-0262. [Epub ahead of print]

PMID:
32213723
2.

Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial.

Inagaki N, Yang W, Watada H, Ji L, Schnaidt S, Pfarr E, Okamura T, Johansen OE, George JT, von Eynatten M, Rosenstock J, Perkovic V, Wanner C, Cooper ME, Alexander JH, Komuro I, Nangaku M.

Diabetol Int. 2019 Oct 22;11(2):129-141. doi: 10.1007/s13340-019-00412-x. eCollection 2020 Apr.

PMID:
32206483
3.

Conditions, pathogenesis, and progression of diabetic kidney disease and early decliner in Japan.

Yoshida Y, Kashiwabara K, Hirakawa Y, Tanaka T, Noso S, Ikegami H, Ohsugi M, Ueki K, Mita T, Watada H, Koya D, Mise K, Wada J, Shimizu M, Wada T, Ito Y, Narita I, Kashihara N, Nangaku M, Matsuyama Y.

BMJ Open Diabetes Res Care. 2020 Mar;8(1). pii: e000902. doi: 10.1136/bmjdrc-2019-000902.

4.

Podocyte-specific deletion of tubular sclerosis complex 2 promotes focal segmental glomerulosclerosis and progressive renal failure.

Iwata W, Unoki-Kubota H, Kato H, Shimizu A, Matsumoto M, Imasawa T, Igarashi A, Matsumoto K, Noda T, Terauchi Y, Nangaku M, Kasuga M, Kaburagi Y.

PLoS One. 2020 Mar 19;15(3):e0229397. doi: 10.1371/journal.pone.0229397. eCollection 2020.

5.

The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.

Hasegawa S, Tanaka T, Saito T, Fukui K, Wakashima T, Susaki EA, Ueda HR, Nangaku M.

Kidney Int. 2019 Dec 25. pii: S0085-2538(19)31247-5. doi: 10.1016/j.kint.2019.12.007. [Epub ahead of print]

6.

Atypical Hemolytic Uremic Syndrome With the p.Ile1157Thr C3 Mutation Successfully Treated With Plasma Exchange and Eculizumab: A Case Report.

Saito D, Watanabe E, Ashida A, Kato H, Yoshida Y, Nangaku M, Ohtsuka Y, Miyata T, Hattori N, Oda S.

Crit Care Explor. 2019 Apr 17;1(4):e0008. doi: 10.1097/CCE.0000000000000008. eCollection 2019 Apr.

7.

Global case studies for chronic kidney disease/end-stage kidney disease care.

Yang CW, Harris DCH, Luyckx VA, Nangaku M, Hou FF, Garcia Garcia G, Abu-Aisha H, Niang A, Sola L, Bunnag S, Eiam-Ong S, Tungsanga K, Richards M, Richards N, Goh BL, Dreyer G, Evans R, Mzingajira H, Twahir A, McCulloch MI, Ahn C, Osafo C, Hsu HH, Barnieh L, Donner JA, Tonelli M.

Kidney Int Suppl (2011). 2020 Mar;10(1):e24-e48. doi: 10.1016/j.kisu.2019.11.010. Epub 2020 Feb 19. Review.

8.

Capturing and monitoring global differences in untreated and treated end-stage kidney disease, kidney replacement therapy modality, and outcomes.

Pecoits-Filho R, Okpechi IG, Donner JA, Harris DCH, Aljubori HM, Bello AK, Bellorin-Font E, Caskey FJ, Collins A, Cueto-Manzano AM, Feehally J, Goh BL, Jager KJ, Nangaku M, Rahman M, Sahay M, Saleh A, Sola L, Turan Kazancioglu R, Walker RC, Walker R, Yao Q, Yu X, Zhao MH, Johnson DW.

Kidney Int Suppl (2011). 2020 Mar;10(1):e3-e9. doi: 10.1016/j.kisu.2019.11.001. Epub 2020 Feb 19. Review.

9.

Coordinated demethylation of H3K9 and H3K27 is required for rapid inflammatory responses of endothelial cells.

Higashijima Y, Matsui Y, Shimamura T, Nakaki R, Nagai N, Tsutsumi S, Abe Y, Link VM, Osaka M, Yoshida M, Watanabe R, Tanaka T, Taguchi A, Miura M, Ruan X, Li G, Inoue T, Nangaku M, Kimura H, Furukawa T, Aburatani H, Wada Y, Ruan Y, Glass CK, Kanki Y.

EMBO J. 2020 Mar 3:e103949. doi: 10.15252/embj.2019103949. [Epub ahead of print]

PMID:
32125007
10.

Group A Streptococcus establishes pharynx infection by degrading the deoxyribonucleic acid of neutrophil extracellular traps.

Tanaka M, Kinoshita-Daitoku R, Kiga K, Sanada T, Zhu B, Okano T, Aikawa C, Iida T, Ogura Y, Hayashi T, Okubo K, Kurosawa M, Hirahashi J, Suzuki T, Nakagawa I, Nangaku M, Mimuro H.

Sci Rep. 2020 Feb 24;10(1):3251. doi: 10.1038/s41598-020-60306-w.

11.

Visualizing fibrosis-hope for ideal markers beyond imaging.

Hirakawa Y, Nangaku M.

Kidney Int. 2020 Mar;97(3):437-438. doi: 10.1016/j.kint.2019.11.029. No abstract available.

PMID:
32087883
12.

Health-related quality of life on combination therapy with peritoneal dialysis and hemodialysis in comparison with hemodialysis and peritoneal dialysis: A cross-sectional study.

Tanaka M, Ishibashi Y, Hamasaki Y, Kamijo Y, Idei M, Kawahara T, Nishi T, Takeda M, Nonaka H, Nangaku M, Mise N.

Perit Dial Int. 2020 Jan 17:896860819894066. doi: 10.1177/0896860819894066. [Epub ahead of print]

PMID:
32063200
13.

Prolyl hydroxylase inhibition protects the kidneys from ischemia via upregulation of glycogen storage.

Ito M, Tanaka T, Ishii T, Wakashima T, Fukui K, Nangaku M.

Kidney Int. 2020 Apr;97(4):687-701. doi: 10.1016/j.kint.2019.10.020. Epub 2019 Nov 9.

PMID:
32033782
14.

Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemia.

Kurata Y, Tanaka T, Nangaku M.

Ann Transl Med. 2019 Dec;7(Suppl 8):S334. doi: 10.21037/atm.2019.09.118. No abstract available.

15.

Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice.

Sugahara M, Tanaka S, Tanaka T, Saito H, Ishimoto Y, Wakashima T, Ueda M, Fukui K, Shimizu A, Inagi R, Yamauchi T, Kadowaki T, Nangaku M.

J Am Soc Nephrol. 2020 Mar;31(3):560-577. doi: 10.1681/ASN.2019060582. Epub 2020 Jan 29.

PMID:
31996409
16.

Modulating the immune system to delay the clinical onset of type 1 diabetes.

Sugahara M, Tanaka T, Nangaku M.

Kidney Int. 2020 Feb;97(2):248-250. doi: 10.1016/j.kint.2019.10.010. Epub 2019 Oct 25. No abstract available.

PMID:
31980070
17.

Inverse Correlation Between Incidence and Mortality of Acute Kidney Injury in Critically Ill Patients: A Systematic Review.

Komaru Y, Inokuchi R, Iwagami M, Hamasaki Y, Nangaku M, Doi K.

Shock. 2020 Jan 21. doi: 10.1097/SHK.0000000000001511. [Epub ahead of print]

PMID:
31977959
18.

Correlation between the Incidence and Attributable Mortality Fraction of Acute Kidney Injury: A Systematic Review.

Komaru Y, Inokuchi R, Iwagami M, Matsuura R, Hamasaki Y, Nangaku M, Doi K.

Blood Purif. 2020 Jan 22:1-8. doi: 10.1159/000505568. [Epub ahead of print]

19.

Outcomes of lactulose plus branched-chain amino acid infusion and lactulose alone for hepatic encephalopathy: A retrospective cohort study using a national inpatient database.

Okada A, Yamana H, Yamaguchi S, Ikeda Kurakawa K, Matsui H, Fushimi K, Nangaku M, Kadowaki T, Yasunaga H.

Hepatol Res. 2020 Jan 13. doi: 10.1111/hepr.13486. [Epub ahead of print]

PMID:
31943593
20.

Recombinant thrombomodulin prevents acute lung injury induced by renal ischemia-reperfusion injury.

Hayase N, Doi K, Hiruma T, Matsuura R, Hamasaki Y, Noiri E, Nangaku M, Morimura N.

Sci Rep. 2020 Jan 14;10(1):289. doi: 10.1038/s41598-019-57205-0.

21.

Vascular Ehlers-Danlos Syndrome Diagnosed in a Patient Initiating Hemodialysis.

Ouchi H, Nishi H, Nakamura M, Hirakawa Y, Tanaka T, Takeda N, Akai T, Ohashi Y, Hoshina K, Takayama T, Nangaku M.

Kidney Int Rep. 2019 Aug 8;4(11):1646-1648. doi: 10.1016/j.ekir.2019.07.020. eCollection 2019 Nov. No abstract available.

22.

The role of anti-complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function.

Fujisawa M, Yasumoto A, Kato H, Sugawara Y, Yoshida Y, Yatomi Y, Nangaku M.

Br J Haematol. 2019 Dec 26. doi: 10.1111/bjh.16297. [Epub ahead of print]

PMID:
31879952
23.

Predicting 3-year mortality based on the tumor necrosis factor alpha concentration in low-flux hemodialysis patients.

Thang LV, Loc ND, Dung NH, Kien NT, Quyen DBQ, Tuan NM, Ha DM, Kien TQ, Dung NTT, Van DT, Van Duc N, Ha NTT, Toan PQ, Usui T, Nangaku M.

Ther Apher Dial. 2019 Dec 19. doi: 10.1111/1744-9987.13463. [Epub ahead of print]

PMID:
31856402
24.

Novel CFHR2-CFHR1 Hybrid in C3 Glomerulopathy Identified by Genomic Structural Variation Analysis.

Sugawara Y, Kato H, Yoshida Y, Fujisawa M, Kokame K, Miyata T, Akioka Y, Miura K, Hattori M, Nangaku M.

Kidney Int Rep. 2019 Sep 19;4(12):1759-1762. doi: 10.1016/j.ekir.2019.09.008. eCollection 2019 Dec. No abstract available.

25.

Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.

Uchida L, Tanaka T, Saito H, Sugahara M, Wakashima T, Fukui K, Nangaku M.

Am J Physiol Renal Physiol. 2020 Feb 1;318(2):F388-F401. doi: 10.1152/ajprenal.00419.2019. Epub 2019 Dec 16.

PMID:
31841388
26.

Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma: A Case Report.

Oki R, Hirakawa Y, Kimura H, Honda K, Hinata M, Abe H, Domoto Y, Tanaka G, Nagase T, Nangaku M.

Intern Med. 2019 Dec 6. doi: 10.2169/internalmedicine.3928-19. [Epub ahead of print]

27.

Kidney International celebrates the 60th anniversary of the International Society of Nephrology.

Ronco P, Rovin B, Nangaku M, Jha V.

Kidney Int. 2019 Dec;96(6):1248-1249. doi: 10.1016/j.kint.2019.10.001. No abstract available.

PMID:
31759479
28.

Insulin promotes sodium transport but suppresses gluconeogenesis via distinct cellular pathways in human and rat renal proximal tubules.

Nakamura M, Tsukada H, Seki G, Satoh N, Mizuno T, Fujii W, Horita S, Moriya K, Sato Y, Kume H, Nangaku M, Suzuki M.

Kidney Int. 2020 Feb;97(2):316-326. doi: 10.1016/j.kint.2019.08.021. Epub 2019 Sep 5.

PMID:
31735358
29.

Diagnostic accuracy of urine dipstick for proteinuria category in Japanese workers.

Usui T, Yoshida Y, Nishi H, Yanagimoto S, Matsuyama Y, Nangaku M.

Clin Exp Nephrol. 2020 Feb;24(2):151-156. doi: 10.1007/s10157-019-01809-3. Epub 2019 Nov 16.

PMID:
31734818
30.

Renal thrombotic microangiopathy during nintedanib treatment for idiopathic pulmonary fibrosis
.

Inoue D, Nishi H, Honda K, Ishii T, Abe H, Sato M, Nangaku M.

Clin Nephrol. 2020 Jan;93(1):47-50. doi: 10.5414/CN109900.

PMID:
31699213
31.

Urinary chloride concentration as a prognostic marker in critically ill patients.

Komaru Y, Doi K, Matsuura R, Yoshida T, Miyamoto Y, Yoshimoto K, Nangaku M.

Nephrology (Carlton). 2019 Oct 31. doi: 10.1111/nep.13674. [Epub ahead of print]

PMID:
31674129
32.

Mitochondrial Damage Causes Inflammation via cGAS-STING Signaling in Acute Kidney Injury.

Maekawa H, Inoue T, Ouchi H, Jao TM, Inoue R, Nishi H, Fujii R, Ishidate F, Tanaka T, Tanaka Y, Hirokawa N, Nangaku M, Inagi R.

Cell Rep. 2019 Oct 29;29(5):1261-1273.e6. doi: 10.1016/j.celrep.2019.09.050.

33.

JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors.

Wakashima T, Tanaka T, Fukui K, Komoda Y, Shinozaki Y, Kobayashi H, Matsuo A, Nangaku M.

Am J Physiol Renal Physiol. 2020 Jan 1;318(1):F14-F24. doi: 10.1152/ajprenal.00323.2019. Epub 2019 Oct 21.

PMID:
31630548
34.

Bioimpedance Spectroscopy-Based Fluid Status in Combined Dialysis Compared With Hemodialysis and Peritoneal Dialysis: A Cross-Sectional Study.

Tanaka M, Ishibashi Y, Hamasaki Y, Kamijo Y, Idei M, Nishi T, Takeda M, Nonaka H, Nangaku M, Mise N.

Ther Apher Dial. 2019 Oct 18. doi: 10.1111/1744-9987.13444. [Epub ahead of print]

PMID:
31626730
35.

Nuclear factor erythroid 2-related factor 2 as a treatment target of kidney diseases.

Ito M, Tanaka T, Nangaku M.

Curr Opin Nephrol Hypertens. 2020 Jan;29(1):128-135. doi: 10.1097/MNH.0000000000000556.

PMID:
31592832
36.

The role of oxidative stress and hypoxia in renal disease.

Honda T, Hirakawa Y, Nangaku M.

Kidney Res Clin Pract. 2019 Dec 31;38(4):414-426. doi: 10.23876/j.krcp.19.063. Review.

37.

Increased albuminuria in bardoxolone methyl-treated type 2 diabetes patients: mere reflection of eGFR improvement?

Ito M, Nangaku M.

Kidney Int. 2019 Oct;96(4):823-825. doi: 10.1016/j.kint.2019.05.033.

PMID:
31543152
38.

Podocyte lipotoxicity in diabetic kidney disease.

Nishi H, Nangaku M.

Kidney Int. 2019 Oct;96(4):809-812. doi: 10.1016/j.kint.2019.07.013. No abstract available.

PMID:
31543147
39.

New measures against chronic kidney diseases in Japan since 2018.

Fukui A, Yokoo T, Nangaku M, Kashihara N.

Clin Exp Nephrol. 2019 Nov;23(11):1263-1271. doi: 10.1007/s10157-019-01786-7. Epub 2019 Sep 9.

40.

Munc18-1-interacting protein 3 mitigates renal fibrosis through protection of tubular epithelial cells from apoptosis.

Nasu K, Kawakami T, Shinohara A, Sakamoto T, Nangaku M.

Nephrol Dial Transplant. 2019 Sep 8. pii: gfz177. doi: 10.1093/ndt/gfz177. [Epub ahead of print]

PMID:
31495893
41.

Profiles of Coagulation and Fibrinolysis Activation-Associated Molecular Markers of Atypical Hemolytic Uremic Syndrome in the Acute Phase.

Sakurai S, Kato H, Yoshida Y, Sugawara Y, Fujisawa M, Yasumoto A, Matsumoto M, Fujimura Y, Yatomi Y, Nangaku M.

J Atheroscler Thromb. 2019 Sep 4. doi: 10.5551/jat.49494. [Epub ahead of print]

42.

Recombinant Thrombomodulin on Neutrophil Extracellular Traps in Murine Intestinal Ischemia-Reperfusion.

Hayase N, Doi K, Hiruma T, Matsuura R, Hamasaki Y, Noiri E, Nangaku M, Morimura N.

Anesthesiology. 2019 Oct;131(4):866-882. doi: 10.1097/ALN.0000000000002898.

PMID:
31453815
43.

Association between intravenous contrast media exposure and non-recovery from dialysis-requiring septic acute kidney injury: a nationwide observational study.

Miyamoto Y, Iwagami M, Aso S, Yasunaga H, Matsui H, Fushimi K, Hamasaki Y, Nangaku M, Doi K.

Intensive Care Med. 2019 Nov;45(11):1570-1579. doi: 10.1007/s00134-019-05755-2. Epub 2019 Aug 26.

PMID:
31451861
44.

Longitudinal change in blood pressure and risk of end-stage renal disease in a community-based cohort in Okinawa.

Usui T, Iseki C, Iseki K, Kawakami K, Nangaku M.

Clin Exp Nephrol. 2019 Nov;23(11):1280-1287. doi: 10.1007/s10157-019-01771-0. Epub 2019 Aug 5.

PMID:
31385160
45.

A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients.

Tsubakihara Y, Akizawa T, Nangaku M, Onoue T, Yonekawa T, Matsushita H, Endo Y, Cobitz A.

Ther Apher Dial. 2020 Apr;24(2):108-114. doi: 10.1111/1744-9987.12962. Epub 2019 Aug 13.

PMID:
31306555
46.

JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.

Fukui K, Shinozaki Y, Kobayashi H, Deai K, Yoshiuchi H, Matsui T, Matsuo A, Matsushita M, Tanaka T, Nangaku M.

Eur J Pharmacol. 2019 Sep 15;859:172532. doi: 10.1016/j.ejphar.2019.172532. Epub 2019 Jul 10.

PMID:
31301309
47.

Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.

Ito S, Shikata K, Nangaku M, Okuda Y, Sawanobori T.

Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1161-1172. doi: 10.2215/CJN.14751218. Epub 2019 Jun 27.

PMID:
31248950
48.

Are SGLT2 inhibitors a targeted treatment for diabetic kidney disease?

Kanda E, Nangaku M.

Kidney Int. 2019 Jul;96(1):8-10. doi: 10.1016/j.kint.2019.04.005. No abstract available.

PMID:
31229049
49.

Light of dawn in Melbourne: SONAR and CREDENCE.

Nangaku M.

Kidney Int. 2019 Jul;96(1):2-4. doi: 10.1016/j.kint.2019.04.004. No abstract available.

PMID:
31229029
50.

Ascitic IL-10 Concentration Predicts Prognosis of Patients Undergoing Cell-Free and Concentrated Ascites Reinfusion Therapy.

Ito T, Hanafusa N, Iwase S, Noiri E, Nangaku M, Nakagawa K, Miyagawa K.

Ther Apher Dial. 2020 Feb;24(1):90-95. doi: 10.1111/1744-9987.12863. Epub 2019 Aug 6.

PMID:
31157953

Supplemental Content

Loading ...
Support Center